8/8/2022 8:05:39 AM
Daiichi Sankyo : Phase 3 Trial Of Patritumab Deruxtecan Initiated In Patients With EGFR-Mutated Metastatic NSCLC
6/27/2022 2:28:06 AM
AstraZeneca Says Enhertu Recommended For EU Approval For Breast Cancer
4/27/2021 5:09:16 AM
Daiichi Sankyo FY EPS 39.11 Yen Vs 66.27 Yen Last Year
1/18/2021 2:03:37 AM
AstraZeneca And Daiichi Sankyo Announce Enhertu Approved In The US For Gastric Cancer